Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

25.48 1.92

Overview

Share price change

24h

Current

Min

24.78

Max

26.07

Key metrics

By Trading Economics

Income

191K

-51M

Sales

6.7M

106M

EPS

-0.46

Profit margin

-47.808

Employees

1,784

EBITDA

-2.1M

-46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+54.48% upside

Dividends

By Acuity

Next Earnings

5 lis 2026

Market Stats

By TradingEconomics

Market Cap

826M

2.9B

Previous open

23.56

Previous close

25.48

News Sentiment

By Acuity

34%

66%

109 / 340 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 sie 2026, 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

31 sie 2026, 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

31 sie 2026, 23:51 UTC

News

Howmet Aerospace shares are higher in after-market hours following Elon Musk's comments on SpaceX's gas turbine blade plans, sparking renewed interest and improved sentiment.

31 sie 2026, 23:46 UTC

News

American Water Works shares are trading higher in after-market hours amid a pending merger settlement approval from the Pennsylvania Public Utility Commission.

31 sie 2026, 23:46 UTC

Correlated Moves
News

Renasant Corp appointed Catherine Mealor as Executive Vice President, effective October 2026. Shares are trading higher in after-market hours following the announcement.

31 sie 2026, 23:46 UTC

News

IQVIA Holdings Inc shares are higher in after-market trading, remaining above their 20-day moving average amid sector growth expectations despite ongoing challenges.

31 sie 2026, 23:41 UTC

News

Quantum Corp shares declined in after-market trading amid broader market sentiment affected by hawkish comments from Federal Reserve Chair Kevin Warsh on inflation.

31 sie 2026, 23:41 UTC

Event
News

Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.

31 sie 2026, 23:41 UTC

News

KeyCorp shares are higher in after-market hours following the appointment of Chris Doll as Chief Strategy Officer, effective August 31, 2026.

31 sie 2026, 23:16 UTC

News

Delek US Holdings Inc. supports Small Refinery Exemptions, enabling increased investments in refineries and U.S. energy infrastructure. Shares are higher in after-market trading.

31 sie 2026, 23:16 UTC

News

Sylvamo Corp shares are higher in after-market hours, buoyed by strong institutional ownership and earnings per share of $1.88.

31 sie 2026, 23:11 UTC

Social Media
News

Coinbase Global shares are lower in after-market trading, amid ongoing interest and developments in the crypto space, including Webull's new services in Canada.

31 sie 2026, 23:11 UTC

News

Under Armour has filed for a mixed shelf offering, including potential debt and equity. Shares traded roughly flat during after-market hours.

31 sie 2026, 23:11 UTC

News

Northrop Grumman secured an $86.1 million contract extension from the U.S. Department of War, boosting shares higher in after-market trading.

31 sie 2026, 23:11 UTC

Correlated Moves
News

The USD/PLN is lower today, influenced by comments from Federal Reserve Chair Kevin Warsh regarding potential interest rate hikes amid rising inflation concerns.

31 sie 2026, 23:06 UTC

News

Oracle Corp is higher in after-market trading, despite challenges including a record low free cash flow yield and concerns about its hyperscaler strategy.

31 sie 2026, 23:06 UTC

News

Ares Capital Corp raised ¥612 billion for its Japan Logistics Development Partners V LP, exceeding its predecessor's size. Shares are higher in after-market hours.

31 sie 2026, 23:06 UTC

Social Media
News

KKR & Co Inc. shares are higher in after-market hours following the firm's support for Wella Co's upcoming IPO on the New York Stock Exchange.

31 sie 2026, 23:06 UTC

News

RTX Corp partners with Lockheed Martin and Tata Advanced Systems for Javelin missile co-production in India. Shares are higher in after-market trading.

31 sie 2026, 23:06 UTC

Event
News

Eli Lilly shares are higher in after-market trading following regulatory clearance for its merger with AtaiBeckley, marking a key milestone in the process.

31 sie 2026, 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

31 sie 2026, 23:06 UTC

Correlated Moves
News

The USD/NOK is trading lower, reflecting a decline since Friday. Market sentiment shifts after comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

31 sie 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and hawkish Fed remarks are supporting gains in CAD/HKD, which is trading near the upper end of its one-month range.

31 sie 2026, 23:06 UTC

Correlated Moves
News

The USD/SGD is lower today, influenced by Federal Reserve comments on inflation and rising Treasury yields. The pair remains near its one-month range's lower end.

31 sie 2026, 23:01 UTC

News

Global Water Resources Inc shares lower after announcing a $0.03 dividend, with analysts projecting earnings of $0.13 per share next year.

31 sie 2026, 23:01 UTC

News

Align Technology shares are lower in after-market trading following the appointment of Quentin Blackford to its Board of Directors, effective immediately.

31 sie 2026, 23:01 UTC

News

elf Beauty Inc shares are lower in after-market trading amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

31 sie 2026, 23:01 UTC

News

Charter Communications shares are lower in after-market hours following the announcement of CFO Jessica Fischer's resignation effective October 15, 2026.

31 sie 2026, 23:01 UTC

News

Avista Corp seeks to reduce natural gas rates by about 11.5%, potentially lowering bills by $7.38. Shares advanced in after-market trading.

31 sie 2026, 23:01 UTC

Social Media
News

Evercore upgraded Duolingo to Outperform, raising its price target to $210. Shares rose after market close, reflecting positive sentiment around the stock.

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

54.48% upside

12 Months Forecast

Average 39.33 USD  54.48%

High 45 USD

Low 36 USD

Based on 3 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Sentiment

By Acuity

109 / 340 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat